The study, led by Mariam M. Faruqui and Ian Lango of the University at Buffalo together with Roberto Pili and Poolakkad S. Satheeshkumar of the University at Buffalo’s Division of Hematology and Oncology and Joel B. Epstein of City of Hope Comprehensive Cancer Center, examined three tumor groups: prostate cancer, renal cell carcinoma, and cancers of the lip, oral cavity, and pharynx. These cancers were chosen deliberately. Prostate cancer is the second leading cause of cancer death among American men, renal cell carcinoma is the most common form of kidney cancer, and smoking is a well-established risk factor for all three malignancies. Because opioid dependence is itself strongly linked to smoking, given that some opioid consumption occurs through smoking, the researchers reasoned that the three cohorts would offer a meaningful window into how dependence interacts with cancer hospitalizations.

Methodologically, the team conducted a retrospective cross-sectional analysis of the 2017 National Inpatient Sample, a 20 percent stratified sample of hospital discharges maintained by the Healthcare Cost and Utilization Project of the Agency for Healthcare Research and Quality that represents roughly 97 percent of all U.S. inpatient discharges. Opioid dependence was identified using the ICD-10-CM code F11.20, which designates uncomplicated opioid dependence, while cancers were captured with corresponding diagnostic codes. The investigators used survey-weighted generalized linear models to account for the complex sampling design, adjusting for age, sex, race, insurance payer, patient location, elective versus non-elective admission, household income by zip code, and comorbidity burden measured by the Elixhauser index. Continuous outcomes such as length of stay and total charges were log-transformed and reported as geometric means because their distributions were strongly skewed.

The scale of the analysis was substantial. Among 208,456 hospitalized prostate cancer patients, 950 had opioid dependence; among 88,105 renal cell carcinoma patients, 610 were opioid dependent; and among 53,770 patients with cancers of the lip, oral cavity, and pharynx, 495 carried the diagnosis. Notably, prostate and renal cell carcinoma patients with opioid dependence were significantly younger than those without it, with mean ages of roughly 67.6 and 59.4 years respectively compared with about 71.5 and 65.3 years in the non-dependent groups. In the oral and pharyngeal cancer cohort, the pattern reversed, with dependent patients being older on average. Length of stay was consistently longer among opioid-dependent patients: the geometric mean stay was 6.01 days versus 4.35 days in prostate cancer, and 6.35 days versus 5.06 days in renal cell carcinoma, while oral and pharyngeal cancer patients with dependence accumulated higher total charges, averaging $91,369 compared with $80,861.

After adjustment, the associations remained striking. Prostate cancer patients with opioid dependence had a coefficient of 1.59 for longer length of stay (95 percent confidence interval 1.14 to 2.21), nearly triple the odds of emergency department referral or admission (adjusted odds ratio 2.60), more than double the odds of fluid and electrolyte disorders (2.25), higher odds of septicemia (1.61), higher odds of anxiety disorders (2.31), and higher odds of depressive disorders (2.22). Perhaps most tellingly, they were significantly less likely to receive mental illness screening, with an adjusted odds ratio of 0.59. In the renal cell carcinoma cohort, opioid dependence was associated with higher emergency department status (1.66), greater fluid and electrolyte disturbance (2.40), higher septicemia (2.61), more anxiety disorders (2.10), and lower mental illness screening (0.55). Comparable findings emerged in the oral and pharyngeal cancer group, where dependence was associated with increased weight loss (2.21), fluid and electrolyte disorders (2.37), anxiety (1.94), and longer stays (1.89).

The disparity analysis revealed a layered picture of inequity. Across all three cancer cohorts, Hispanic patients with opioid dependence were more likely to have septicemia than their White counterparts, with adjusted odds ratios of roughly 1.27 to 1.33 depending on the tumor type. Black patients with opioid dependence had significantly longer hospital stays than White patients in all three cohorts, with coefficients around 1.20 to 1.29. Screening for mental illness was consistently less frequent among Hispanic, Black, and Asian or other minority patients compared with White opioid-dependent patients across the cancer groups. Insurance type and neighborhood income also mattered: Medicaid beneficiaries experienced longer stays and greater weight loss, while privately insured patients tended to have shorter stays and fewer emergency admissions, and patients from low-income zip codes faced prolonged hospitalizations in the prostate and oral cancer cohorts.

The biological plausibility of these findings is reinforced by prior laboratory and clinical work. Studies have suggested that opioids may promote the survival of cancerous cells in renal cell carcinoma, enhance tumor aggressiveness through the survivin pathway, and modulate the molecular metabolism of clear cell renal cell carcinoma while reducing macrophage and immune cell numbers. Opioid exposure has also been linked to increased recurrence of prostate cancer and to tumor migration, invasion, and growth. At the same time, the authors emphasize that opioids remain indispensable analgesics for cancer-related pain, used in roughly a third of cancer treatment contexts, which creates a delicate clinical balance between relieving suffering and managing the risks of dependence. A pooled meta-analysis cited in the study estimates that opioid use disorder affects about 8 percent of patients broadly, with a 23.5 percent risk of use disorder among those treated for cancer-related pain, and that approximately 2.1 million people in the United States live with opioid use disorder.

The authors frame opioid dependence as a multifaceted condition shaped by both biological and psychosocial forces. On the biological side, dependence has been associated with altered cytokine and chemokine signaling, sleep disturbances, and food deprivation; on the psychological side, psychiatric comorbidity, dopaminergic reward circuitry, and memory consolidation processes all contribute to risk. Prior research has documented high rates of neurocognitive impairment, particularly in learning and memory, among opioid-dependent adults, and genetic studies suggest a causal relationship between predisposition to opioid dependence and risk of major depressive disorder and stress-related disorders. Anxiety sensitivity and pain-related anxiety, rather than pain intensity itself, appear to drive much of the misuse behavior, and negative mood may be the shared subfacet of anxiety and depression that fuels opioid abuse. These mechanisms help explain why the study found such strong associations between dependence and psychiatric comorbidity in hospitalized cancer patients.

The septicemia findings carry particular weight. Previous national research has documented that septicemia is among the most common co-occurring diagnoses in opioid-dependent hospitalizations, and that sepsis rates tied to opioid-related admissions have risen as the opioid crisis has deepened. Septic patients with opioid-related hospitalizations tend to be younger with fewer comorbidities but more bloodstream infections from bacterial and fungal pathogens, and a significant proportion of sepsis deaths, especially among patients under fifty, occur in those hospitalized for opioid-related issues. The new study extends this literature into oncology, showing that within cancer populations, dependence amplifies the risk of bloodstream infection, a complication that can derail cancer treatment, prolong recovery, and increase mortality.

The authors acknowledge limitations inherent to their design. The National Inpatient Sample records discharges rather than individuals, so a single patient could theoretically be counted more than once, although readmission databases make this unlikely to meaningfully distort results. The dataset lacked information on cancer stage, tumor size, and specific treatment regimens, which prevented the researchers from adjusting for disease severity. Reliance on ICD-10-CM coding introduces the possibility of coding errors, though the authors argue that validation across multiple cancer cohorts and consistent findings support the robustness of the approach. As with any cross-sectional analysis of administrative data, residual confounding and the absence of temporal sequencing limit causal interpretation, and the team calls for validation in independent registries or institutional datasets.

The study’s conclusion is a call to action rather than an argument against opioid prescribing. The authors stress that opioid availability remains crucial for high-quality cancer pain management, and they propose that in exceptional clinical situations, including patients at high risk of mental disorder, exact criteria must be developed for controlling cancer pain that allow safe opioid delivery while accounting for both the biological and psychosocial dimensions of dependence. Given that opioid-dependent cancer patients in this study were less likely to be screened for mental illness despite having higher rates of anxiety and depression, the findings point toward an urgent need for integrated behavioral health services, equitable screening practices, and targeted resources for the most vulnerable populations. Increasing care and resources for opioid-dependent cancer patients, the authors write, could be critical to improving outcomes for those already burdened by both malignancy and addiction.